Esperion Therapeutics, Inc.2025财年第一财季实现净利润-40.46百万美元，同比减少166.31%

市场透视2025-05-12

5月12日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2025财年第一财季净利润为-40.46百万美元，同比减少166.31%；其中营业收入为65.00百万美元，同比减少52.90%，每股基本收益为-0.21美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债7.50亿美元，其中短期债务1.15...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534238759?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-12 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2534238759","market":"us","top_or_hot":-1,"title":"Esperion Therapeutics, Inc.2025财年第一财季实现净利润-40.46百万美元，同比减少166.31%","media":"市场透视","content":"<div>\n<p>5月12日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2025财年第一财季净利润为-40.46百万美元，同比减少166.31%；其中营业收入为65.00百万美元，同比减少52.90%，每股基本收益为-0.21美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债7.50亿美元，其中短期债务1.15...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000103a6db2bd0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics, Inc.2025财年第一财季实现净利润-40.46百万美元，同比减少166.31%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics, Inc.2025财年第一财季实现净利润-40.46百万美元，同比减少166.31%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-12 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000103a6db2bd0&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月12日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2025财年第一财季净利润为-40.46百万美元，同比减少166.31%；其中营业收入为65.00百万美元，同比减少52.90%，每股基本收益为-0.21美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债7.50亿美元，其中短期债务1.15...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000103a6db2bd0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000103a6db2bd0&s=b","article_id":"2534238759","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000103a6db2bd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2534238759","pubTimestamp":1746979233,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月12日，Esperion Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-40.46百万美元，同比减少166.31%；其中营业收入为65.00百万美元，同比减少52.90%，每股基本收益为-0.21美元。从资产负债表来看，Esperion Therapeutics, Inc.总负债7.50亿美元，其中短期债务1.15亿美元，资产负债比为0.44，流动比率为1.18。机构评级：截至2025年5月12日，当前有7家机构对Esperion Therapeutics, Inc.目标价做出预测，其中目标均价为5.79美元，其中最低目标价为1.50美元，最高目标价为16.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ESPR":"Esperion Therapeutics Inc."},"translate_title":"Esperion Therapeutics, Inc. achieved net profit of-US $40.46 million in the first fiscal quarter of fiscal year 2025, a year-on-year decrease of 166.31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":0.9,"LENZ":1},"content_text":"5月12日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2025财年第一财季净利润为-40.46百万美元，同比减少166.31%；其中营业收入为65.00百万美元，同比减少52.90%，每股基本收益为-0.21美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债7.50亿美元，其中短期债务1.15亿美元，资产负债比为0.44，流动比率为1.18。机构评级：截至2025年5月12日，当前有7家机构对Esperion Therapeutics, Inc.目标价做出预测，其中目标均价为5.79美元，其中最低目标价为1.50美元，最高目标价为16.00美元。公司简介：Esperion Therapeutics Inc 是一家制药公司。该公司专门为患有低密度脂蛋白胆固醇升高的患者开发和商业化可获得的、口服的、每日一次的非他汀类药物。该公司的业务是研究、开发和商业化治疗低密度脂蛋白胆固醇升高患者的治疗方法。其产品包括NEXLETOL， NEXLIZET， NILEMDO和NUSTENDI。该公司在一个运营部门管理其业务，即研究，开发和商业化治疗低密度脂蛋白胆固醇（LDL-C）水平升高的患者的疗法。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534238759","isCrawlerRequest":true}